Introduction Bristol-Myers Squibb is a leading pharmaceutical company with a strong pipeline. However, the stock is been stagnant in 2020 and therefore remains significantly undervalued here at the beginning of 2021. With this video I attempt to illustrate reasons why the market has been neglecting this blue-chip and then elaborate on whether it is justified …